Chimerix And FDA’s Compassionate-Use Solution
This article was originally published in The Pink Sheet Daily
A media storm is over and Chimerix has resumed focus on the Phase III trial of its lead program, thanks to quick work by the company and FDA to design a trial providing access to brincidofovir in immunocompromised patients with adenovirus.
You may also be interested in...
New internal policy says the US agency cannot force a drug maker to supply an unapproved drug to a patient for expanded access and that the provider must seek company approval to provide the product.
Given that 'right to try' is intended to be a patient-centered proposal, patient organizations are a strong voice in opposition, working behind the scenes to revise – or entirely exclude – the legislation as part of the user fee package. But the bill also has powerful advocates among Senate Republicans and in the Trump Administration.
Fourteen user fee goal dates are on the October calendar, including three novel agents, according to the Pink Sheet US FDA Performance Tracker.